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Abstract Community-acquired pneumonia (CAP) is a ma-
jor cause of death in developing countries and of morbidity
in developed countries. The objective of the study was to
define the causative agents among children hospitalized for
CAP defined by WHO guidelines and to correlate etiology
with clinical severity and surrogate markers. Investigations
included an extensive etiological workup. A potential
causative agent was detected in 86% of the 99 enrolled
patients, with evidence of bacterial (53%), viral (67%), and
mixed (33%) infections. Streptococcus pneumoniae was
accounted for in 46% of CAP. Dehydration was the only
clinical sign associated with bacterial pneumonia. CRP and
PCT were significantly higher in bacterial infections.
Increasing the number of diagnostic tests identifies potential
causes of CAP in up to 86% of children, indicating a high
prevalence of viruses and frequent co-infections. The high
proportion of pneumococcal infections re-emphasizes the
importance of pneumococcal immunization.
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Abbreviations
CAP Community-acquired pneumonia
WHO World Health Organization
CRP C-reactive protein
PCT Procalcitonin
NPA Nasopharyngeal aspirates
BTS British Thoracic Society
NS Nasopharyngeal swabs
WBC White blood cell
URS Upper respiratory symptoms
hMPV Human metapneumovirus
Introduction
Childhood community-acquired pneumonia (CAP) is a
common and serious health care problem, responsible for
one fifth of children’s deaths around the world (2 million),
70% occurring in developing countries [45]. In Europe and
North America, the annual incidence of CAP is approxi-
mately 40 cases per 1,000 and therefore also represents a
major cause of morbidity [19]. There are two major
difficulties in the diagnosis of CAP. The first one is how
to define pneumonia, particularly in the young age group in
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which both pneumonia and viral lower respiratory tract
infections are common conditions. The World Health
Organization (WHO) has defined pneumonia and subse-
quent treatment on strict clinical signs (Table 1) [1, 7, 17].
A prospective study showed that the WHO guidelines can
also be applied in developed countries, as recommended by
the guidelines of the British Thoracic Society (BTS) [2, 11].
The second difficulty is to identify the causative agent of
pneumonia in children. This remains challenging for a
number of reasons: endo-tracheal aspirates cannot be
obtained routinely, nasopharyngeal swabs (NS) only show
colonization by normal flora including the bacteria most
commonly causing pneumonia, and bacteremia is demon-
strated in less than 10% of bacterial CAP. Therefore, the
etiology of CAP remains often unknown, with the
consequence that many children get an antibiotic treatment
for non-bacterial infections, contributing to the increase of
bacterial resistance to antibiotics [9, 41]. The aims of this
study, performed before the routine implementation of the
heptavalent pneumococcal vaccine in Switzerland, were to
define, as strictly as possible, the causative agents of
pneumonia among children aged from 2 months to 5 years
hospitalized for CAP on the basis of WHO clinical criteria,
and to determine which factors could help clinicians to
discriminate bacterial from viral pneumonia.
Material and methods
Study design and population
Participation to this prospective and descriptive study was
offered to all consecutive children aged 2 months to 5 years
old presenting with CAP according to the WHO criteria
(Table 1) consecutively admitted to the children’s unit of
the university hospitals of Lausanne and Geneva between
March 2003 and December 2005. They were classified
according to initial severity. Children with actively treated
asthma, an underlying chronic disease, immunosuppres-
sion, or wheezing were excluded. Children with wheezing
were specifically excluded because wheezing is considered
to be a symptom of asthma and/or viral bronchiolitis and
not of pneumonia, and therefore these children are not
treated with antibiotics. Cough and fever, associated signs
and symptoms, the use of antibiotics in the month before
admission, and the main features of the clinical course were
recorded. The Ethical committees of both institutions
approved the study protocol. Signed consent was obtained
from informed parents.
Routine samples for inflammatory parameters
On admission, a blood sample was taken for total white
blood cell count (WBC) with manually verified differential
count. Serum CRP and PCT (Lumitest®, Brahms, Berlin,
Germany) were measured.
Radiology
A senior radiologist, blinded to clinical and laboratory
findings, reviewed all chest radiographs and assigned a
standardized description of the X-ray as proposed by the
WHO working group [5]: the presence of consolidation
or pleural effusion with parenchymal infiltrate defined
pneumonia.
Microbiology
On admission, before starting an antibiotic treatment,
peripheral blood cultures, and during the winter epidemic,
a rapid antigen detection test for RSV (Coris or Becton
Dickinson), were performed. Within 8 h after admission,
nasopharyngeal aspirates (NPA) were obtained after respi-
ratory physiotherapy for viral and bacterial culture, PCR
analysis, and viral antigen detection. PCR analysis was
performed for Mycoplasma pneumoniae and Chlamydia
pneumoniae. RT-PCR assays were performed for 13 viruses
including Influenza A and B, RSV A and B, Rhinovirus,
Parainfluenza 1–3, enterovirus, human metapneumovirus,
coronavirus OC43, E229, and NL 63 as previously
described [15, 16, 25]. In the present study, all the assays
were used as qualitative tools. PCR for M. pneumoniae and
C. pneumoniae were done by a multiplex real-time PCR
according to Welti et al. [44]. Viral antigen detection was
performed for Adenovirus, Para-influenza 1–3, RSV, and
Influenza A and B by indirect immunofluorescence (Argene
Antibodies) or ELISA.
Serology
Serum samples were taken at admission and approximately
3 weeks after hospitalization, then stored at −20°C and
subsequently transported on dry ice to the laboratories. The
Table 1 Clinical definition of pneumonia according to the WHO
Fevera Tachypneab Chest
indrawing
Not able
to drink
and/or
central
cyanosis
Stage I (non-severe) + +
Stage II (severe) + + +
Stage III (very severe) + + + +
a Fever≥38°C axillary
b Respiratory rate >50/min (2–11 months) and >40/min (1–5 years)
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laboratory was unaware of clinical data. Antibodies for
Influenza A and B; Parainfluenza 1, 2, and 3; RSV;
Adenovirus; and M. pneumoniae were detected by the
complement fixation method. Paired samples were tested in
the same run. Acute infection was defined by a fourfold rise
or a titer higher than 1/80. Serologic tests for C. pneumo-
niae were done by using a micro-immunofluorescence test
(MRL Diagnostics). A fourfold rise between the acute and
convalescent sera or an initial titer higher than fourfold the
positive cut off value (1:16) were considered as indicative
of a recent infection, as previously described [26]. Serum
IgG antibodies to pneumolysin were measured by indirect
ELISA on antigen-coated Immulon plates (Thermo Lab-
system), following 60 min incubation at 37°C. Results were
compared to a pool of purified human immunoglobulins
(Endobulin, Baxter) used as standard and expressed in
ELISA Units/ml. Samples with a rise greater than twofold
between acute or convalescent sera and/or acute serum
antibody titers greater than 300 EU/ml were scored
positive. These limits have been previously demonstrated
to be a reliable method for the serological diagnosis of
pneumococcal exposure [22, 35].
Detection of Streptococcus pneumonia by PCR
The blood samples were taken at the time of admission and
sera were frozen at −70°C in order to be analyzed in a
second phase. The detection of S. pneumoniae was
performed by real-time PCR with the Taqman method.
The specific target was the pneumolysin gene. Briefly,
200 µl of blood specimen were pre-lysed with 80 μl of lysis
buffer (Bacterial lysis buffer, Roche Diagnostics) and with
30 μl of a cocktail of enzymes (Lyt030 enzymmix, Roche
Diagnostic). After an incubation period of 30 min at 37°C,
the sample was automatically extracted with a MagNa Pure
compact instrument using the MagNa Pure compact
isolation kit I. Five microliters of the eluted DNA were
then amplified in triplicate with a Taqman ABI Prism 7700
Sequence Detector (Applied Biosystems). Any significant
curve before the cycle 40, was considered as a positive
signal, the positive cut off was defined as 1,000 copy/ml [8,
27, 43].
Etiologic classification criteria
The criteria for viral infection were a positive viral culture,
viral antigen, positive viral serology, or viral PCR. A
bacterial infection was considered if a blood culture, a
pleural fluid culture, a pneumococcal PCR, or a serologic
assay was positive. Atypical and typical bacteria were
grouped together. Subjects with criteria of both viral and
bacterial infections were considered to have infections of
mixed etiology.
Treatment
Patients were treated with a course of parenteral antio-
biotics first (cefuroxime (n=46), ceftriaxone (n=22),
amoxiclavulanic acid (n=38), floxapen (n=1)), followed
by oral antibiotics (amoxiclavulanic acid or cefuroxime) for
a total duration of 2 to 25 days. Parenteral cefuroxime was
initially associated with clarithromycin in four patients or
switched for vancomycin and amoxyclavulanic acid or for
amoxycillin and clindamycin in two patients with pleural
effusion.
Statistical analysis
Data were analyzed using Epi Info 6.04d (Center for
Disease Control and Prevention, Atlanta, GA, USA).
Standard parametric and non-parametric statistical tests
were done according to distribution and variance of studied
variables. The level of statistical significance was defined
as p≤0.05. Kappa statistics were computed using PAIRS
module, version 1.33, of Pepi for Windows software.
Results
Population characteristics
A total of 111 children were eligible during the study
period. Ninety-nine children were finally enrolled (six
patients were excluded because of the impossibility to
obtain samples and, after initial consent, five parents
decided to interrupt the study). Among these patients, 51
were females (52%). The average age was 29 months.
According to WHO criteria, nine patients (9%) requiring
hospitalization had non-severe pneumonia; 67 (68%)
patients, severe pneumonia; and 23 (23%), very severe
pneumonia. All subjects had fever or a recent history of
fever and tachypnea. Many patients showed a number of
other symptoms: 96 had cough (97%), 80 (81%) had
feeding difficulties, 45 (45%) had vomiting, and 17 (17%)
abdominal pain. Other symptoms were tiredness or apathy
(n=7); thoracic pain (n=5); or upper respiratory symptoms
(URS): rhinitis (n=6), sore throat (n=3), and ear pain
(n=2). The average temperature at admission was 39.1°C.
Breath sounds were abnormal in 78 patients (79%) and 25
(26%) were dehydrated. Antibiotics were given to 27
patients (27%) during 30 days before hospitalization.
Although there was a large variation in the number of
monthly hospitalizations, no clear seasonal pattern was
observed. The average duration of hospitalization was
2 days ranging from a few hours to 25 days. Twenty-six
children (26%) required supplemental oxygen therapy, nine
patients (9%) needed a gastric feeding tube, and nine (9%)
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a thoracic drainage. Three patients were transferred to the
pediatric intensive care unit, two of them requiring non-
invasive assisted ventilation (Table 2).
Overall results
Table 3 shows the number of samples obtained for each
test. Viral and atypical bacterial serology, were the most
difficult to obtain (follow-up blood sample), as well as
nasopharyngeal aspirates (NPA), notably in children with-
out upper respiratory tract involvement. A potential
causative agent was detected in 85 (86%) of the 99 patients.
Evidence of bacterial infection alone was demonstrated in
19 patients (19%) and viral infection alone in 33 (33%)
cases. Mixed bacterial-viral infection was found in 33
(33%) patients (Fig. 1).
Bacterial infection
Only one patient had a positive blood culture (S. pneumo-
niae), while three other blood cultures were contaminated
by a coagulase-negative Staphylococci. One patient had a
Group A β-hemolytic Streptococcus in pleural fluid culture.
Overall, bacteria with or without co-infecting pathogens
were identified in 53% of the cases (52 patients).
Pneumococcal pneumonia was diagnosed in 45 patients
Table 2 Demographic and clinical results of 99 patients hospitalized for community-acquired pneumonia and correlation with etiology
Characteristics Total Bacterial Viral Mixed Unknown
pathogen
P Value
No. of patient (%) 99 19 (19) 33 (33) 33 (33) 14 (14)
Age, months (0.25; 0.75)a 29.4 (17; 48) 23.4 (19; 48) 25.1 (15; 38) 42.9 (24; 52) 22.4 (11; 34) 0.033c,e
Gender (m/f) 48/51 11/8 17/16 14/19 6/8 0.692d
Antibiotics before hospitalization 27 8 8 9 2 0.327d
Pneumonia stage Ib (non-severe) 9 2 5 2 0 0.650d
Pneumonia stage IIb (severe) 67 13 19 24 11
Pneumonia stage IIIb (very severe) 23 4 9 7 3
Temperature at admission (0.25; 0.75)a 39.1 (38.5; 39.8) 39.0 (38.5; 39.8) 39.2 (38.7; 39.8) 39.1 (38.3; 39.6) 38.8 (38.5; 39.5) 0.308
Symptoms of painb,f 22 2 6 13 1 0.026d,g
Vomitingb 45 8 13 18 6 0.634d
URSb 11 1 4 3 3 0.505d
Dehydrationb 25 9 2 8 6 0.003d,h
Oxygen requirementb 26 5 11 7 3 0.693d
Radiological consolidationb 77 16 25 26 10 0.911d
CRP mg/la 167 (60; 200) 200 (100; 204) 88 (21; 194) 200 (117; 250) 142 (23; 192) 0.009c,i
PCT ng/mla 6.0 (1; 14) 11.5 (5; 18) 2.0 (0.5; 7.5) 11.0 (3; 18) 3.0 (0.5; 4) 0.018c,j
WBC count (G/L)a 15.0 (9; 21) 15.0 (11; 19) 12.0 (7; 21) 16.0 (10; 21) 15.5 (11; 18) 0.591c
Band forms (G/L)a 1.85 (0.6–3.8) 2.65 (1.3; 3.8) 1.4 (0.5; 2.6) 1.82 (1.0; 4.0) 1.31 (0.6; 3.1) 0.417c
Duration of hospitalization, daysa
(0.25; 0.75)
2 (2; 4) 3 (2; 9) 2 (1; 4) 2 (2; 4) 2 (1; 3) 0.255d
a The median value was used (25th quantile; 75th quantile)
b Number of patients
c The Kruskal–Wallis one-way analysis of variance was used
d The Chi-square analysis was used
e Further Kruskal–Wallis analyses showed that, after exclusion of unknown pathogen, results were significant between viral and mixed pneumonia
(P=0.017) but not between bacterial and mixed (P=0.143) or viral and bacterial (P=0.425)
f Abdominal, dorsal or thoracic pain
g Further Chi-square analyses showed that, after exclusion of unknown pathogen, results were significant between mixed and bacterial group (P=
0.027), but not between mixed and viral group (P=0.057), neither between bacterial and viral group (P=0.461)
h Further Chi-square analyses showed that difference was significant between viral and bacterial (P=0.0004) or mixed (P=0.039) group but not
between bacterial and mixed group (P=0.087)
i Further Chi-square analyses showed that, after exclusion of unknown pathogen, results were significant between all bacterial infections (bacterial
+ mixed) and viral infections (P=0.003), but not between bacterial and mixed (P=0.803), neither between bacterial and viral (P=0.023).
j Further Chi-square analyses showed that, after exclusion of unknown pathogen, results were significant between all bacterial infections (bacterial
+ mixed) and viral infections (P=0.009), but not between bacterial and mixed (P=0.805), neither between bacterial and viral (P=0.016)
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(46% overall), based on PCR (21/45, 47%), rising antibody
titer (14/45, 31%), and/or high antibody titers at admission
(30/45, 66%). Despite a negative PCR, 53% (24/45) of
patients had serological evidence of acute pneumococcal
infection. The single child with a pneumococcal bacteremia
had a positive PCR and serology. S. pneumoniae was
diagnosed alone in 12 patients (63% of bacterial etiology).
Mixed pneumococcal-viral infections occurred in 28
patients (85% of mixed pneumonia), with a large spectrum
of concomitant viruses (Table 4).
Viral infection
Overall, 66 among the 99 children (67%) had evidence of
an acute viral infection (Fig. 2; Table 4). PCR was very
sensitive to detect several viruses. In no patient with a
negative viral PCR, could a viral infection be detected
using another method. There was a significant relationship
between age and etiological category (Table 2).
Clinical or inflammatory parameters and etiology
Excluding patients with undetermined etiology, univariate
analyses showed that dehydration was the only clinical sign
significantly more represented in the bacterial group of
pneumonia. Indeed, 47% of children with bacterial pneumo-
nia, while only 24% in the mixed group and 6% in the viral
pneumonia group (P=0.003), showed signs of dehydration,
(Table 2). Other symptoms were not significantly associated
with etiology. In particular, URS were not significantly more
frequent in the viral group. The proportion of patients in each
clinical severity category (WHO stages) did not differ
significantly according to etiology (P=0.698). Analysis of
laboratory data showed that children with bacterial pneumo-
nia overall had higher inflammatory parameters: CRP and
PCT values were significantly higher in the bacterial
pneumonia group when mixed and bacterial pneumonia
were analyzed together (Table 2). However, inflammatory
indices were not statistically associated with clinical severity.
For a cut off level of 60 mg/l the sensitivity of CRP was 88%
but the specificity was low (44%). For a cut off level of 5 ng/
ml the sensitivity of PCT was 72% and the specificity 58%.
Total white blood cell count and band forms were not
significantly associated with etiology. The proportion of
children treated with antibiotics before hospitalization, did
not differ according to the etiological category (Chi square,
P=.33). The average duration of hospitalization was related
to clinical severity.
Clinical and radiological data
On admission, breath sounds were described as completely
normal in 21 (21%) patients. In 78 patients with abnormal
auscultation, the most constant sign was diminished breath
sounds (59 patients). Chest X-ray was abnormal in 97 of 98
patients (99%). Radiological consolidation was present in
77 (79%) patients. Overall percent agreement between the
presence of diminished breath sounds and radiological
consolidation was 60.2% with a Kappa coefficient of 0.11
(95% CI—0.07 to 0.29), confirming very poor agreement.
There was no association between radiological description
and severity or etiology of pneumonia.
Discussion
One hundred and eleven immunocompetent children, aged
between 2 months and 5 years old, hospitalized for
pneumonia, were studied prospectively to elucidate the
bacterial (single) 14 % bacterial (multiple) 5% viral (single) 21%
viral (multiple) 12% mixed (33%) unknown (14%)
Fig. 1 Aetiology of pneumonia in 99 hospitalized children. Five
patients, in the bacterial group, had a dual bacterial pneumonia (four
including S. pneumoniae and Mycoplasma pneumoniae, one including
S. pneumoniae and Group A streptococcus)
Table 3 Microbiological armamentarium and number of samples performed
Blood
culture
NPA
(viral culture)
NPA
(viral AG)
NPA
(viral PCR)
NPA (M. pneumoniae,
C. pneumoniae PCR)
Viral
serologya
Serology for M.
pneumoniae and
C. pneumoniaea
Pneumoc.
serologyb
Pneumoc
PCR
No. of exams
(total=99) (%)
98 (99) 85 (86) 80 (81) 93 (94) 89 (90) 71 (72) 71 (72) 98 (99) 97 (98)
No. of positive
(%)
1 (1) 15 (17) 12 (15) 59 (63) 8 (9) 17 (24) 12 (17) 40 (41) 21 (22)
a Convalescent serology
b Acute and/or convalescent serology
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factors that could help the clinician to differentiate viral
from bacterial pneumonia. Ninety-nine patients met the
inclusion criteria in the strict respect of the WHO definition
of pneumonia. A multiple diagnostic approach combining
microbiology, serology, and biochemical assays was used to
define the spectrum of pathogens that cause pneumonia in
children unimmunized against S. pneumoniae. Overall, a
potential causative agent was detected in 86% of the
children, confirming previous studies showing that the
more tests are done, the more potential causes emerge [23,
24, 31, 39]. Evidence of bacterial infection was demon-
strated in 53% of patients.
S. pneumoniae was documented in 45% of the cases,
corroborating previous reports such as the one by Michelow
et al. [32]. A virus was found in 67% of the children. In 33%
of the cases, a concurrent bacterial and viral infection was
found. Antibiotic treatment before hospitalization doesn’t
seem to be a factor of misdiagnosis. Our study showed that
in children fulfilling the WHO clinical definition of
pneumonia and severity criteria, diagnosis was confirmed
by radiological consolidation in 78% of cases. The poor
agreement between auscultation and radiological consolida-
tion confirms the poor sensitivity and specificity of auscul-
tation to diagnose pneumonia in young children [11]. As
previously described [14, 28] chest X-ray and blood cultures
were not helpful in discriminating etiological categories of
pneumonia. Duration of hospitalization was correlated with
clinical severity essentially because WHO criteria define
children with stage III pneumonia as requiring oxygen
supplementation. Pain was the only clinical sign significantly
associated with bacterial pneumonia. Acute-phase surrogate
markers such as CRP and PCT, were significantly higher in
bacterial infection regardless of the presence or absence of
co-infecting viruses, corroborating several previous analyses
[20, 33, 37] even if these findings are controversial in recent
literature [13]. Further analysis is needed to determine the
exact utility of these tests, as the sensibility and specificity
with a bacterial cut off level were quite low. Finally, our data
could not show a significant correlation between clinical
severity and etiology of pneumonia [24].
As reported previously [12, 21, 40, 42], our data confirm
the high prevalence of viruses and showed the frequent
occurrence of co-infection in childhood CAP. The viruses
most commonly found were rhinovirus (30%) and hMPV
(20%), confirming the recent findings that these viruses
frequently involved in pediatric CAP [3, 11, 36, 38]. RSV
was less represented than in other reports [6], probably
because all patients with typical bronchiolitis were strictly
excluded. Several points still have to be elucidated: whether
viruses are the direct cause of pneumonia, whether they
Table 4 Pathogens identified in 99 hospitalized children with community-acquired pneumonia
Pathogen No Co-infection Co-infection with bacteriaa Co-infection with virusesa Total no. of episodes, %
Bacteria S. pneumoniae 12 10 28 45 (46)
S. Group A β hemolytic 0 1 1 1 (1)
M. pneumoniae 2 5 5 11(11)
C. pneumoniae 0 6 6 7 (7)
Viruses Influenza A or B 0 8 10 14 (14)
Parainfluenza 1–3 2 8 8 13 (13)
Rhinovirus 7 11 10 20 (20)
hMPV 5 5 7 13 (13)
RSV A or B 6 3 7 13 (13)
Enterovirus 1 8 11 13 (13)
Adenovirus 0 6 5 7 (7)
Coronavirus 0 4 7 7 (7)
a The categories of co-infection with bacteria or with viruses are not mutually exclusive
multiple viruses (44%) Rhinovirus (18%) hMPV (9%) RSV (9%)
Influenza A (6%) Parainfluenza 1-3 (8%) Enterovirus (3%) Adenovirus (3%)
Fig. 2 Distribution of viruses
associated with pneumonia. A
virus was found in 66 (67%) of
the 99 patients hospitalized for
pneumonia
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create conditions favoring secondary bacterial infections, or
whether their presence plays a relatively minor role in CAP
pathogenesis.
The main limitation to our study is the lack of validation
and standardization of all microbiological cut off values,
especially those concerning S. pneumoniae [4]. One of the
major obstacles to improve the understanding of CAP is
probably that we are still underdiagnosing pneumococcal
and possibly other bacterial pneumonia. The use of a single
antigen (pneumolysin) for the serological diagnosis of
pneumococcal pneumonia may be a limitation, as well as
the difficulty, in our study, to obtain convalescent serum
samples (available for only 73% of the children). Therefore,
it remains difficult to distinguish a real acquired infection
from a recent colonization. As recently described by
Nakayama et al. [34], the use of PCR to detect bacterial
pneumonia could be a useful additional diagnostic method.
However, the fact that 46% of young children with CAP
requiring hospitalization demonstrated evidence of an acute
pneumococcal infection, is in accordance with the demon-
strated impact of pneumococcal immunization [10, 18, 29,
30]. Finally, our results do not support the hypothesis that
clinical severity depends on the causal agent. However, for
ethical and practical reasons we chose to study only
hospitalized children. Therefore, we have a limited number
of patients with stage I pneumonia whom we usually treat
in the ambulatory setting. A further study should include
this group in order to confirm, with a greater number of
patients, the non-association between clinical severity at
admission and etiology.
In conclusion, this study used strict WHO clinical
criteria to select suitable subjects to undergo an extensive
microbiological etiological workup using a complete set of
modern diagnostic tools. Our data confirm a high preva-
lence of viruses and the frequent occurrence of co-infection
in childhood CAP. Dehydration and surrogate markers of
inflammation such as CRP and PCT were significantly
higher in children with bacterial pneumonia. Therefore,
further analyses should be performed in order to find out
which children should be treated with antibiotics and in
which children antibiotics could be withheld safely. The
high proportion of S. pneumoniae in severe CAP re-
emphasized the importance of pneumococcal immunization
and antibiotics for treatment of CAP in young children.
Other studies should also be performed to evaluate the
epidemiology of moderate to severe bacterial pneumonia
after introduction of pneumococcal immunization.
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